News

Stents, Self-Apposing Stent, Stentys

Stentys announced that the Self-Apposing Stent has been implanted more than 10,000 times in patients worldwide

InspireMD, MGuard, CGuard, drug-eluting stent, MASTER II, CARENET, trials

InspireMD, Inc. announced results from two important clinical trials. Thirty-day results from the MASTER II trial, which enrolled 310 of a planned 1,114 patients were presented at a major...

bioresorbable stents

Ongoing clinical trials of bioresorbable stents continue to show positive data for the devices, which are widely expected to overtake metallic stents in the coming years if the data trend...

stents, bioresorbable, clinical trial, clinical study

Reva Medical initiated patient enrollment with its Fantom bioresorbable drug-eluting scaffold. 

Wearable technologies, possible changes to stenting practices, state legislation on energy drinks, expanded use of minimally invasive heart repair procedures, and the development of a new class of...

Clinical trial/study, stents, venous therapies

Veniti Inc. announced that it has enrolled the first United States patients in the Virtus trial of the Veniti VICI Venous Stent System.

Boston Scientific, EVOLVE II, Synergy, bioresorbable stent

In the first successful United States trial of a bioabsorbable polymer stent, the Boston Scientific Synergy everolimus-eluting bioabsorbable polymer platinum chromium coronary stent system met its...

stents, Cobra, celonova

CeloNova BioSciences, Inc., announced that positive first-in-man (FIM) clinical trial results found its Cobra PzF coronary stent system with an advanced nano-thin coating of Polyzene-F polymer to...

DAPT study

Patients who took dual antiplatelet therapy medications beyond the standard 12 months after coronary stent placement were significantly less likely to develop blood clots within their stents or to...

Stentys, coronary stent, MiStent SES, Micell Technologies Inc.

Micell Technologies Inc. announced commercialization plans for its MiStent Sirolimus Eluting Absorbable Polymer...

Optimizing the treatment of coronary artery disease with a new foundation for future stent innovations, Medtronic Inc. announces CE mark and international launch of the Resolute Onyx ...

Five-year results from the largest and longest-running clinical trial of a drug-eluting stent for treating peripheral arterial disease (PAD) confirmed long-term patency for patients treated...

VIVA, VIVA Physicians, Peripheral, Carotid Artery Device, clinical trial results

Viva Physicians, a not-for-profit organization in the field of vascular medicine and intervention, announce clinical trial results and other new happenings at Viva '14, hosted in Las Vegas,...

The U.S. Food and Drug Administration (FDA) has cleared the Abbott family of Xience everolimus-eluting coronary stents for the additional indication to treat coronary chronic total occlusions (...

DAIC Editor Dave Fornell

The key take away messages from the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium were bioresorable stents and transcatheter valve technologies will likely...

Everflex stent, Covidien, ev3

The U.S Food and Drug Administration (FDA) cleared the EverFlex Self-Expanding Peripheral Stent System and outlined...

The use of stents has improved management and outcomes of coronary artery disease, and clinical trials are attempting to prove the same will be true for superficial femoral artery disease....

October 20, 2014 — Boston Scientific Corp. has initiated the PLATINUM Diversity trial to evaluate the clinical performance of the Promus Premier Everolimus-Eluting Platinum...

Stenting Safe Effective Long-term Stroke Prevention

Using stents to keep neck arteries open is just as effective as invasive neck surgery for long-term prevention of fatal and disabling strokes, reports an international trial led by UCL (University...

“Once patients have survived cancer, they don't die from cancer, they die from heart disease. Cardio-oncology is about making sure that doesn't happen," said Juan Carlos Plana, M.D.